Merck (MRK) EBIT (QoQ) (2009 - 2026)
Merck (MRK) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn |
| 10 | Sanofi | 55.31 Bn | 47.93 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.30% |
| Mar 31, 2026 | -262.69% |
| Dec 31, 2025 | -173.74% |
| Sep 30, 2025 | 100.42% |
| Jun 30, 2025 | -41.95% |
| Mar 31, 2025 | 626.32% |
| Dec 31, 2024 | 3,320.00% |
| Sep 30, 2024 | -99.56% |
| Jun 30, 2024 | 6.15% |
| Mar 31, 2024 | 135.75% |
| Dec 31, 2023 | -539.38% |
| Sep 30, 2023 | 114.49% |
| Jun 30, 2023 | -3,290.94% |
| Mar 31, 2023 | 25.00% |
| Dec 31, 2022 | -4.84% |
| Sep 30, 2022 | -229.52% |
| Jun 30, 2022 | 152.22% |
| Mar 31, 2022 | -1,582.86% |
| Dec 31, 2021 | -98.07% |
| Sep 30, 2021 | 230.93% |